Menu
Not yet recruiting NCT06741098

A Study of NCR100 Injection for the Treatment of Knee Osteoarthritis（ KOA）

Phase I / Phase II Interventional Knee Osteoarthritis

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: NCR100, 0.9% Normal saline.
Who it may be relevant to
Registry conditions: Knee Osteoarthritis. Basic parameters: 40 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Center list to be confirmed — check the primary protocol.
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Study to Evaluate the Safety, Tolerability and Efficacy of NCR100 Injection for the Treatment of Knee Osteoarthritis（ KOA）

Overview

This clinical study is to investigate the safety and efficacy of NCR100 injection in subjects with knee osteoarthritis (KOA). It contains two parts dose-escalating, and blind random study in adult KOA subjects.

Detailed description

Knee osteoarthritis(KOA) is a kind of degenerative joint disease characterized by chronic inflammation loss of articular cartilage and subchondral bone remodeling.In China, the estimated number of patients diagnosed with KOA reached 37.35millon. The aim of this sudy is to evaluate the safety tolerability and efficacy of human pluripotent stem cell derived mesenchymal stromal cells (NCR100) injection in the treatment of subjects with knee osteoarthritis.

Interventions

  • Biological NCR100
    Subjects will receive multiple intra-articular NCR100 injections.
  • Other 0.9% Normal saline
    Subjects will receive multiple intra-articular 0.9% Normal saline injections.

Primary outcome measures

  • Dose-Limiting Toxicity(DLT) [Time frame: 4 weeks after first injection]
  • The Western Ontario and McMaster Universities osteoarthritis index(WOMAC) [Time frame: 48 weeks after first injection]
Secondary outcome measures (4)
  • Adverse Event(AE) or Serious Adverse Event(SAE) [Time frame: Within 48 weeks of the first infusion]
  • Visual analogue scale (VAS) [Time frame: 8 weeks, 12 weeks, 24 weeks, 36 weeks and 48 weeks]
  • Differences in changes from baseline at 8 weeks, 12 weeks, 24 weeks and 36 weeks of the Western Ontario and McMaster Universities Arthritis Index (WOMAC) between the experimental groups and the control group [Time frame: 8 weeks, 12 weeks, 24 weeks and 36 weeks]
  • Differences in changes from baseline to 24 weeks and 48 weeks in cartilages with various regions [Time frame: 24 weeks and 48 weeks]

Eligibility criteria

Inclusion criteria

  • Subjects who understand and voluntarily sign the Informed Consent Form（ICF） before the enrolment;
  • Age: 40-65 years old, both genders;
  • Diagnosis of knee osteoarthritis based on American College of Rheumatology criteria;
  • Subjects with KOA who have persistent pain for more than six months
  • Kellgren-Lawrence grade: II-III

Exclusion criteria

  • Subjects previously diagnosed of secondary knee osteoarthritis, or those diagnosed with hip/ankle joint disease requiring medical intervention;
  • Suffering from other diseases that impair knee function or joints;
  • Have received stem cell therapy;
  • Have knee injury history;
  • Experienced knee surgery, or plan to undergo knee surgery;
  • Received analgesics to relieve pain before Investigational Medicinal Product(IMP) injections;
  • Have used traditional Chinese medicine to treat KOA within 4 weeks;
  • Have used intra-articular injection of drugs to treat KOA within 12 weeks;
  • Received glucosamine,chondroitin sulfate, or diacetate therapy before investigational drug intervention within 12 weeks;
  • Subjects with acute phase of knee osteoarthritis;
  • Severe deformity of the knee;
  • Known or suspected allergy or a history of allergies;
  • Abnormal results of laboratory examination as follows: Hepatic Insufficiency （Alanine Aminotransferase>2xULN or Aspartate aminotransferase \[ast\]>2xULN) renal dysfunction (creatinine clearance rate ≤60ml/min or blood urea nitrogen(BUN) > 2× ULN), Coagulation Defects (INR > 1.5) or severe hematological diseases (Grade 3 or above anemia \[Hb < 8 g/dL\], Grade 2 or above thrombocytopenia platelet count(PLT) < 75×10\^9/L) ;
  • BMI≥30kg/m\^2
  • Severe systemic infection or local knee joint infection;
  • Have received systemic glucocorticoid therapy before intervention or need to take systemic glucocorticoid therapy during the treatment;
  • Have a history of acute myocardial infarction or severe heart diseases,QT prolongation;
  • Subjects with peripheral or central nervous system disorders that may interfere assessments;
  • Have contraindications to Magnetic Resonance Imaging(MRI)
  • Subjects who are unable to walk on his own;
  • Subjects with alcohol/drug addiction/abuse or mental disorders;
  • Pregnant or lactating, or unable to comply with contraceptives within 6 months after end of study;
  • Have participated in other clinical trials within 12 weeks before the screening;
  • Severe and poorly controlled comorbidities;

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Triple blind
Primary purpose
Treatment

Study locations

Center list to be confirmed — check the primary protocol.

Identifiers

NCT: NCT06741098 · NCR100-1002

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗